ACR President Carol A. Langford, MD, MPH, highlights the importance of research in the field and where to find resources and initiatives within the ACR to support, fund, inspire, and enhance innovation. For more on this important topic, see Dr. Langford’s column in the January issue of The Rheumatologist.
RA: How High Is the Toll?
Patients with RA not only suffer from functional limitations, but also face increased healthcare costs, primarily due to prescription drug use, says Dr. Yinan Huang.
President’s Corner: ACR Initiatives Support Research at Every Level
For me, few ACR events bring home our connection as a rheumatology community more than our annual meeting, ACR Convergence. In addition to its many important opportunities for networking and education, one aspect of the meeting that always inspires me is the research. Research represents one of the three priorities of my presidential term because…
Youthful Exuberance: The Year in Review for Pediatric Rheumatology
WASHINGTON, D.C.—It is no small task to summarize an entire year’s worth of research accomplishments in any field of medicine, let alone one as complex as rheumatology. At ACR Convergence 2024, the Pediatric Year in Review not only provided a thoughtful summary, but also grouped advances along several different themes. Immune Health & More Jessica…
Prevalence of Fibromyalgia & Widespread Pain in Psoriatic Arthritis: Association with Disease Severity Assessment in a Large U.S. Registry
According to a new study, fibromyalgia prevalence is elevated in PsA and is associated with elevated disease measures, confounding reliable disease assessment for treat-to-target goals.
Top Research in Psoriatic Arthritis Presented at ACR Convergence 2024
Editor’s note: What research on psoriatic arthritis (PsA) presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. Dr. Pisetsky, a professor of medicine and immunology…
AC&R Study Summary: Standardizing Treatment for Moderately Severe JDM
Why was this study done? Juvenile dermatomyositis (JDM) is the most common type of idiopathic inflammatory myopathy in childhood, and most patients have a chronic disease course requiring prolonged administration of systemic glucocorticoids and immunosuppressive agents. The initial management for patients with moderately severe JDM is relatively standardized, typically including methotrexate and systemic glucocorticoids with…
3 AC&R Study Summaries: Lupus Fog, SSc Variance By Ethnicity & Tuberculosis Screening in New DMARD Users
Lupus Fog? By Laura C. Plantinga, PhD, Patricia P. Katz, PhD, S. Sam Lim, MD, MPH, C. Barrett Bowling, MD, MSPH, & Jinoos Yazdany, MD, MPH Why was this study done? Perceived cognitive impairment (i.e., lupus fog) is common in systemic lupus erythematosus (SLE). However, comprehensive, multidomain assessments of objective cognitive function are rarely performed….
What’s New in Large Vessel Vasculitis
The large vessel vasculitides were a major focus of the 21st International Vasculitis Workshop held in Barcelona in April. The biennial conference brings together specialists from multiple disciplines, including rheumatology, nephrology and immunology, to discuss cutting-edge vasculitis research. This article reviews important points regarding the pathogenesis, diagnosis and management of both giant cell arteritis and…
CAR-T Cells: Are We Closer To Drug-Free Remission Than We Think?
Most Sunday mornings, I make myself an exceptional cup of pour-over coffee and sit down on my deck with the latest issue of the New England Journal of Medicine. I check out the image of the week. I read the case report with pen in hand, racing to diagnose the patient before the authors spill…
- 1
- 2
- 3
- …
- 123
- Next Page »